Movement Alert｜INSILICO Falls 5.78% in Regular Trading, Sector-Wide Weakness Overshadows New IND Approval

Market Focus08-03

On August 3, INSILICO fell 5.78% in regular trading, trading at 43.06 HKD/share, with turnover of approximately 517 million HKD. The decline came despite the company announcing on the same day that its co-developed oral NLRP3 inhibitor ISM8969/HT-001 had received NMPA Investigational New Drug approval for the treatment of Parkinson's disease.

The positive pipeline milestone failed to offset broad selling pressure across the Life Sciences Tools and Services sector. GENSCRIPT BIO fell 7.81%, WUXI APPTEC declined 0.19%, WUXI BIO dropped 0.98%, WUXI XDC lost 1.16%, and XTALPI fell 1.61%. The pullback also follows a period of significant gains for INSILICO, which rose nearly 6% on July 31 after receiving FDA Fast Track designation for ISM6331 and posted strong momentum through late July driven by multiple strategic partnerships and a mid-year profit guidance of USD 33.5-39.5 million net profit versus a prior-year loss.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1120232971?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-03 13:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120232971","market":"us","top_or_hot":-1,"title":"Movement Alert｜INSILICO Falls 5.78% in Regular Trading, Sector-Wide Weakness Overshadows New IND Approval","media":"Market Focus","content":"<p><p>On August 3, INSILICO fell 5.78% in regular trading, trading at 43.06 HKD/share, with turnover of approximately 517 million HKD. The decline came despite the company announcing on the same day that its co-developed oral NLRP3 inhibitor ISM8969/HT-001 had received NMPA Investigational New Drug approval for the treatment of Parkinson's disease.</p><p>The positive pipeline milestone failed to offset broad selling pressure across the Life Sciences Tools and Services sector. GENSCRIPT BIO fell 7.81%, WUXI APPTEC declined 0.19%, WUXI BIO dropped 0.98%, WUXI XDC lost 1.16%, and XTALPI fell 1.61%. The pullback also follows a period of significant gains for INSILICO, which rose nearly 6% on July 31 after receiving FDA Fast Track designation for ISM6331 and posted strong momentum through late July driven by multiple strategic partnerships and a mid-year profit guidance of USD 33.5-39.5 million net profit versus a prior-year loss.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜INSILICO Falls 5.78% in Regular Trading, Sector-Wide Weakness Overshadows New IND Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜INSILICO Falls 5.78% in Regular Trading, Sector-Wide Weakness Overshadows New IND Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-03 13:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 3, INSILICO fell 5.78% in regular trading, trading at 43.06 HKD/share, with turnover of approximately 517 million HKD. The decline came despite the company announcing on the same day that its co-developed oral NLRP3 inhibitor ISM8969/HT-001 had received NMPA Investigational New Drug approval for the treatment of Parkinson's disease.</p><p>The positive pipeline milestone failed to offset broad selling pressure across the Life Sciences Tools and Services sector. GENSCRIPT BIO fell 7.81%, WUXI APPTEC declined 0.19%, WUXI BIO dropped 0.98%, WUXI XDC lost 1.16%, and XTALPI fell 1.61%. The pullback also follows a period of significant gains for INSILICO, which rose nearly 6% on July 31 after receiving FDA Fast Track designation for ISM6331 and posted strong momentum through late July driven by multiple strategic partnerships and a mid-year profit guidance of USD 33.5-39.5 million net profit versus a prior-year loss.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03696","symbol_name":"英矽智能","start_time":0,"source_url":"","article_id":"1120232971","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120232971","pubTimestamp":1785734806,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 3, INSILICO fell 5.78% in regular trading, trading at 43.06 HKD/share, with turnover of approximately 517 million HKD. The decline came despite the company announcing on the same day that...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03696":"英矽智能"},"translate_title":"走势警报|INSILICO 常规交易中下跌 5.78%，全行业疲软给新的 IND 批准蒙上阴影","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03696":1},"content_text":"On August 3, INSILICO fell 5.78% in regular trading, trading at 43.06 HKD/share, with turnover of approximately 517 million HKD. The decline came despite the company announcing on the same day that its co-developed oral NLRP3 inhibitor ISM8969/HT-001 had received NMPA Investigational New Drug approval for the treatment of Parkinson's disease.The positive pipeline milestone failed to offset broad selling pressure across the Life Sciences Tools and Services sector. GENSCRIPT BIO fell 7.81%, WUXI APPTEC declined 0.19%, WUXI BIO dropped 0.98%, WUXI XDC lost 1.16%, and XTALPI fell 1.61%. The pullback also follows a period of significant gains for INSILICO, which rose nearly 6% on July 31 after receiving FDA Fast Track designation for ISM6331 and posted strong momentum through late July driven by multiple strategic partnerships and a mid-year profit guidance of USD 33.5-39.5 million net profit versus a prior-year loss.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1120232971","isCrawlerRequest":true}